In another first-in-human trial (UMIN000011519), eight patients with refractory AML or high-risk MDS were treated twice with autologous T cells engineered to express a TCR specific for the WT1234-243 peptide in an HLA-A*24:02-restricted manner, along with siRNAs to eliminate expression of endogenous TCR chains, followed by sequential WT1 peptide vaccines. Here, WT1 is linked to acute myeloid leukemia.